Related Experiment Video
Updated: Jun 27, 2025
Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia
Published on: September 18, 2013
TYM-3-98, a novel selective inhibitor of PI3Kδ, demonstrates promising preclinical antitumor activity in B-cell
Si-Yue Lou1, Fan-Li Zheng2, Yong-Mei Tang3
1School of Pharmaceutical Sciences, Zhejiang Chinese Medical University, Hangzhou 311403, China; Academy of Chinese Medical Sciences, Zhejiang Chinese Medical University, Binwen Rd, Hangzhou, Zhejiang 310053, China.
Aims:
PI3Kδ is expressed predominately in leukocytes and is commonly found to be aberrantly activated in human B-cell lymphomas. Although PI3Kδ has been intensively targeted for discovering anti-lymphoma drugs, the application of currently approved PI3Kδ inhibitors has been limited due to unwanted systemic toxicities, thus warranting the development of novel PI3Kδ inhibitors with new scaffolds.
Main Methods:
We designed TYM-3-98, an indazole derivative, and evaluated its selectivity for all four PI3K isoforms, as well as its efficacy against various B-cell lymphomas both in vitro and in vivo.
Key Findings:
We identified TYM-3-98 as a highly selective PI3Kδ inhibitor over other PI3K isoforms at both molecular and cellular levels. It showed superior antiproliferative activity in several B-lymphoma cell lines compared with the approved first-generation PI3Kδ inhibitor idelalisib. TYM-3-98 demonstrated a concentration-dependent PI3K/AKT/mTOR signaling blockage followed by apoptosis induction. In vivo, TYM-3-98 showed good pharmaceutical properties and remarkably reduced tumor growth in a human lymphoma xenograft model and a mouse lymphoma model.
Significance:
Our findings establish TYM-3-98 as a promising PI3Kδ inhibitor for the treatment of B-cell lymphoma.
Insights
A novel indazole derivative, TYM-3-98, shows high selectivity as a PI3Kδ inhibitor. It effectively reduces B-cell lymphoma growth in preclinical models, offering a promising new therapeutic option.
Area of Science:
- Oncology
- Pharmacology
- Molecular Biology
Background:
- Phosphoinositide 3-kinase delta (PI3Kδ) is predominantly expressed in leukocytes and often aberrantly activated in human B-cell lymphomas.
- Approved PI3Kδ inhibitors face limitations due to systemic toxicities, necessitating the development of novel agents with new scaffolds.
Purpose of the Study:
- To design and evaluate TYM-3-98, a novel indazole derivative, as a selective PI3Kδ inhibitor.
- To assess the in vitro and in vivo efficacy of TYM-3-98 against B-cell lymphomas.
Main Methods:
- TYM-3-98 was designed as an indazole derivative.
- Selectivity for PI3K isoforms and efficacy against B-cell lymphomas were evaluated in vitro and in vivo.
- Pharmacological properties and tumor growth reduction were assessed in preclinical models.
Main Results:
- TYM-3-98 demonstrated high selectivity for PI3Kδ over other PI3K isoforms at molecular and cellular levels.
- It exhibited superior antiproliferative activity against B-lymphoma cell lines compared to idelalisib.
- TYM-3-98 effectively inhibited PI3K/AKT/mTOR signaling, induced apoptosis, and reduced tumor growth in vivo.
Conclusions:
- TYM-3-98 is a highly selective PI3Kδ inhibitor with promising preclinical efficacy.
- These findings establish TYM-3-98 as a potential therapeutic candidate for B-cell lymphoma treatment.
Related Concept Videos
01:22PI3K/mTOR/AKT Signaling Pathway
02:34Inhibition of Cdk Activity
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...